Table 1 The major targets of QYG for AD treatment and its relevant topological parameters
From: A network pharmacology-based study on Alzheimer disease prevention and treatment of Qiong Yu Gao
Uniprot ID | Protein name | Gene name | Degree | Betweenness centrality | Closeness centrality | Average shortest path length |
|---|---|---|---|---|---|---|
P18031 | Tyrosine-protein phosphatase non-receptor type 1 | PTPN1 | 26 | 0.066106 | 0.337931 | 2.959184 |
P05230 | Fibroblast growth factor 1 | FGF1 | 25 | 0.041648 | 0.342657 | 2.918367 |
P09038 | Fibroblast growth factor 2 | FGF2 | 24 | 0.033146 | 0.334471 | 2.989796 |
P10636 | Microtubule-associated protein tau | MAPT | 18 | 0.038501 | 0.309637 | 3.229592 |
P08172 | Muscarinic acetylcholine receptor M2 | CHRM2 | 16 | 0.02588 | 0.319739 | 3.127551 |
P00918 | Carbonic anhydrase 2 | CA2 | 15 | 0.069146 | 0.345679 | 2.892857 |
P11229 | Muscarinic acetylcholine receptor M1 | CHRM1 | 15 | 0.026518 | 0.324503 | 3.081633 |
P40763 | Signal transducer and activator of transcription 3 | STAT3 | 15 | 0.011336 | 0.315113 | 3.173469 |
P10275 | Androgen receptor | AR | 14 | 0.037305 | 0.360958 | 2.770408 |
P11511 | Cytochrome P450 19A1 | CYP19A1 | 14 | 0.024461 | 0.332767 | 3.005102 |
P28845 | Corticosteroid 11-beta-dehydrogenase isozyme 1 | HSD11B1 | 14 | 0.029686 | 0.345679 | 2.892857 |
Q13133 | Oxysterols receptor LXR-alpha | NR1H3 | 14 | 0.008421 | 0.311111 | 3.214286 |
P04035 | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | HMGCR | 13 | 0.030442 | 0.34087 | 2.933673 |
P60568 | Interleukin-2 | IL2 | 13 | 0.011053 | 0.316129 | 3.163265 |
Q92731 | Estrogen receptor beta | ESR2 | 12 | 0.016322 | 0.329412 | 3.035714 |
P04150 | Glucocorticoid receptor | NR3C1 | 11 | 0.019069 | 0.331641 | 3.015306 |
P11473 | Vitamin D receptor | VDR | 11 | 0.007378 | 0.311111 | 3.214286 |